81 related articles for article (PubMed ID: 24161159)
21. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
Perahia DG; Kajdasz DK; Walker DJ; Raskin J; Tylee A
Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
[TBL] [Abstract][Full Text] [Related]
22. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
[TBL] [Abstract][Full Text] [Related]
23. Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial.
Ball S; Marangell LB; Lipsius S; Russell JM
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():217-21. PubMed ID: 23313564
[TBL] [Abstract][Full Text] [Related]
24. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.
Papakostas GI; Worthington JJ; Iosifescu DV; Kinrys G; Burns AM; Fisher LB; Homberger CH; Mischoulon D; Fava M
Depress Anxiety; 2006; 23(3):178-81. PubMed ID: 16528701
[TBL] [Abstract][Full Text] [Related]
25. Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder.
Meighen KG
J Child Adolesc Psychopharmacol; 2007 Feb; 17(1):121-7. PubMed ID: 17343560
[TBL] [Abstract][Full Text] [Related]
26. Preclinical discovery of duloxetine for the treatment of depression.
Torres-Sanchez S; Perez-Caballero L; Mico JA; Elorza J; Berrocoso E
Expert Opin Drug Discov; 2012 Aug; 7(8):745-55. PubMed ID: 22680253
[TBL] [Abstract][Full Text] [Related]
27. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.
Davidson JR; Wittchen HU; Llorca PM; Erickson J; Detke M; Ball SG; Russell JM
Eur Neuropsychopharmacol; 2008 Sep; 18(9):673-81. PubMed ID: 18559291
[TBL] [Abstract][Full Text] [Related]
28. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
29. Use of effect size to determine optimal dose of duloxetine in major depressive disorder.
Pritchett YL; Marciniak MD; Corey-Lisle PK; Berzon RA; Desaiah D; Detke MJ
J Psychiatr Res; 2007; 41(3-4):311-8. PubMed ID: 16934840
[TBL] [Abstract][Full Text] [Related]
30. Predictors of duloxetine versus other treatments among veterans with diabetic peripheral neuropathic pain: a retrospective study.
Zhao Y; Liu J; Zhao Y; Thethi T; Fonseca V; Shi L
Pain Pract; 2012 Jun; 12(5):366-73. PubMed ID: 21951753
[TBL] [Abstract][Full Text] [Related]
31. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
[TBL] [Abstract][Full Text] [Related]
32. Duloxetine in treatment of anxiety symptoms associated with depression.
Dunner DL; Goldstein DJ; Mallinckrodt C; Lu Y; Detke MJ
Depress Anxiety; 2003; 18(2):53-61. PubMed ID: 12964171
[TBL] [Abstract][Full Text] [Related]
33. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
Hudson JI; Wohlreich MM; Kajdasz DK; Mallinckrodt CH; Watkin JG; Martynov OV
Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562
[TBL] [Abstract][Full Text] [Related]
34. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
Baldwin DS; Loft H; Dragheim M
Eur Neuropsychopharmacol; 2012 Jul; 22(7):482-91. PubMed ID: 22209361
[TBL] [Abstract][Full Text] [Related]
35. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.
Raskin J; Wiltse CG; Dinkel JJ; Walker DJ; Desaiah D; Katona C
J Clin Psychopharmacol; 2008 Feb; 28(1):32-8. PubMed ID: 18204338
[TBL] [Abstract][Full Text] [Related]
36. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
Perahia DG; Kajdasz DK; Desaiah D; Haddad PM
J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
[TBL] [Abstract][Full Text] [Related]
37. Effects of baseline depression severity on remission rates with duloxetine and placebo in anxious and nonanxious patients with major depression.
Nelson JC
J Clin Psychopharmacol; 2011 Oct; 31(5):682-4. PubMed ID: 21881463
[No Abstract] [Full Text] [Related]
38. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?
Perahia DG; Pritchett YL; Desaiah D; Raskin J
Int Clin Psychopharmacol; 2006 Nov; 21(6):311-7. PubMed ID: 17012978
[TBL] [Abstract][Full Text] [Related]
39. Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial.
Englisch S; Knopf U; Scharnholz B; Kuwilsky A; Deuschle M; Zink M
J Psychopharmacol; 2009 Nov; 23(8):875-82. PubMed ID: 18583440
[TBL] [Abstract][Full Text] [Related]
40. Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective.
Cui Z; Faries DE; Gelwicks S; Novick D; Liu X
J Med Econ; 2012; 15(1):134-44. PubMed ID: 22014076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
